The venture was found in Asia in China. The leading representative office of defined VC is situated in the Shanghai.
Among the most successful fund investment fields, there are E-Commerce, Medical. Among the various public portfolio startups of the fund, we may underline 91 Boyuan Wireless, Mofang Gongyu, Xiaodian The fund has exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.
We also calculated 9 valuable employees in our database.
The increased amount of exits for fund were in 2013. Deals in the range of 10 - 50 millions dollars are the general things for fund. The typical startup value when the investment from DT Capital Partners is 100-500 millions dollars. Comparing to the other companies, this DT Capital Partners performs on 22 percentage points less the average number of lead investments. Considering the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the DT Capital Partners, startups are often financed by Tiger Fund, Ceyuan Ventures, Shunwei Capital. The meaningful sponsors for the fund in investment in the same round are Tiger Fund, Tencent Holdings, Northern Light Venture Capital. In the next rounds fund is usually obtained by Samsung Ventures, Formation 8, Tiger Fund.
Related Funds
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Sincetrue | 07 Aug 2024 | Suzhou, Jiangsu, China | |||
Worg Pharmaceuticals | $170M | 29 Jun 2023 | Shangcheng District, Zhejiang, China | ||
Drug Farm | $27M | 16 May 2023 | Shanghai, China | ||
Parylene | $8M | 30 Jan 2023 | Jiading, Shanghai, China | ||
STARTDT | $15M | 01 Dec 2022 | - | ||
Beilai Bio | $46M | 15 Apr 2022 | Irvine, California, United States | ||
CytoNiche | $46M | 03 Mar 2022 | Dongcheng District, Beijing, China | ||
Deep Blue Aerospace | $30M | 18 Jan 2022 | China, Beijing, China | ||
Going-Link | $100M | 26 Nov 2021 | Shanghai, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Sincetrue | 07 Aug 2024 | Suzhou, Jiangsu, China | |||
Worg Pharmaceuticals | $170M | 29 Jun 2023 | Shangcheng District, Zhejiang, China | ||
Drug Farm | $27M | 16 May 2023 | Shanghai, China | ||
Parylene | $8M | 30 Jan 2023 | Jiading, Shanghai, China | ||
STARTDT | $15M | 01 Dec 2022 | - | ||
Beilai Bio | $46M | 15 Apr 2022 | Irvine, California, United States | ||
CytoNiche | $46M | 03 Mar 2022 | Dongcheng District, Beijing, China | ||
Deep Blue Aerospace | $30M | 18 Jan 2022 | China, Beijing, China | ||
Going-Link | $100M | 26 Nov 2021 | Shanghai, China |